An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation and Sham taVNS in Dysphagia Post Stroke, sponsored by Cairo University. Not yet recruiting. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study investigates the effect of transcutaneous auricular vagus nerve stimulation (taVNs) on dysphagia rehabilitation in sub-acute stroke patients.
This study investigates the effect of transcutaneous auricular vagus nerve stimulation (taVNs) on dysphagia rehabilitation in sub-acute stroke patients. Participants will be randomly assigned to conventional dysphagia rehabilitation with either true taVNS or a sham taVNS. Each patient will receive three sessions per week for four weeks. Each session will last 45 minutes, with taVNS on for 30 minutes during the session in the study group. Same goes for the control group with sham taVNS .
Swallowing function will be assessed by Fiberoptic-Endoscopic Evaluation Of Swallowing (FEES) before and after the intervention period.
875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.
This study's planned enrollment of 40 is below the median of 60 across 580 interventional studies indexed under Deglutition Disorders.
Browse Deglutition Disorders studies →Cairo University is the lead sponsor of 4,965 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will receive conventional dysphagia rehabilitation consisting of exercises aimed at increasing the strength of supra-hyoid muscles and the pharyngeal constrictors. Thermal-tactile stimulation will also be applied. Alongside that , sham taVNS will be applied.
Device: Sham taVNS
This group will receive conventional dysphagia rehabilitation consisting of exercises aimed at increasing the strength of supra-hyoid muscles and the pharyngeal constrictors. Thermal-tactile stimulation will also be applied. Alongside that , true taVNS will be applied at 250μs , 25 HZ, and intensity to the patient's tolerance.
Device: Transcutaneous Auricular Vagus Nerve Stimulation
taVNS with parameters set at 250 μs , 25 HZ, and current intensity to the patient's tolerance.
Also known as: True taVNS
Sham taVNS
Penetration-Aspiration Scale (PAS) score
Swallowing function will be assessed before and after intervention by comparing the patient's score on the Penetration-Aspiration Scale (PAS) as seen during Fiberoptic Endoscopic Examination Of Swallowing Function (FEES)
Time frame: At enrollment and after 4 weeks of intervention
FOIS
Functional oral intake scale
Time frame: At enrollment and after 4 weeks of intervention
Arabic EAT-10
Arabic version of the eating assessment tool (EAT-10)
Time frame: At enrollment and after 4 weeks of intervention
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.
Of 290 non-industry interventional studies with no phase under Deglutition Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 3 months is below that.
Counting every sponsor, half of 299 studies reached it within 21 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.